Cyclosporine A treatment for relapsed subcutaneous panniculitis-like T-cell lymphoma: a case with long-term follow-up.
10.5045/kjh.2012.47.2.146
- Author:
Se Il GO
1
;
Won Sup LEE
;
Myung Hee KANG
;
In Suk KIM
;
Dong Chul KIM
;
Jeong Hee LEE
Author Information
1. Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Korea. lwshmo@gshp.gsnu.ac.kr
- Publication Type:Case Report
- Keywords:
Subcutaneous panniculitis-like T-cell lymphoma;
Cyclosporine;
Treatment outcome
- MeSH:
Cyclosporine;
Drug Therapy, Combination;
Follow-Up Studies;
Humans;
Lymphoma;
Lymphoma, T-Cell;
Panniculitis;
Phenotype;
Recurrence;
Subcutaneous Tissue;
T-Lymphocytes;
Treatment Outcome
- From:Korean Journal of Hematology
2012;47(2):146-149
- CountryRepublic of Korea
- Language:English
-
Abstract:
Subcutaneous panniculitis-like T-cell lymphoma (SPTL) is a distinctive lymphoma characterized by an infiltration of subcutaneous tissue by neoplastic cytotoxic T cells. There was no distinction between TCR alpha/beta phenotype and TCR gamma/delta phenotype, and anthracycline-based chemotherapy was usually used for both. Here, we report a patient with recurrent SPTL who achieved a second long-term complete remission by repeated cyclosporine A (CsA) treatment. From 2000 to 2001, the patient received anthracycline-based combination chemotherapy. However, the treatment did not induce long-term remission. In 2002, he received cyclosporine treatment for about 6 months. This resulted in a 5-year remission that ended in relapse in 2008. He received CsA treatment once again and attained a second long-term remission. This case suggests that re-treatment with CsA can be a good option for relapsed SPTL cases and can result in long-term remission.
